Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
加入2012年5月

推文

你已封鎖 @AblynxABLX

你確定要查看這些推文嗎?查看推文並不會將 @AblynxABLX 解除封鎖

  1. 已轉推
    7月26日

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

  2. 已轉推
    7月20日
  3. 7月20日

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

  4. 6月27日

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

  5. 6月26日

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

  6. 5月29日

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

  7. 5月22日

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

  8. 5月18日

    Meet our experts and recruiters (booth 99) @

  9. 5月11日
  10. 5月11日

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

  11. 5月10日

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

  12. 5月2日

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

  13. 4月7日

    Annual Report 2016 is available online - view via

  14. 4月7日
  15. 已轉推
    3月6日

    Compelling data for developed psoriasis nanobody in collaboration

  16. 已轉推
    2月28日

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

  17. 已轉推
    2月24日

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

  18. 2月23日

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

  19. 2月9日

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

  20. 2月6日

看來要一段時間讀取資料。

Twitter 可能已超出負載,或發生暫時性的小問題。請再試一次,或造訪 Twitter 狀態以取得更多資訊。

    你也可能也會喜歡

    ·